Neurogene Inc. (NGNE) Financials

NGNE Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 263.1 million 25.4 million
Dec. 31, 2025 289.2 million 24.3 million
Sept. 30, 2025 287.8 million 22.3 million
June 30, 2025 297.3 million 24.1 million

NGNE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -26.4 million 3.6 million
Dec. 31, 2025 -16.8 million 3.4 million
Sept. 30, 2025 -19.8 million 3.4 million
June 30, 2025 -19.6 million 3.4 million

NGNE Net Income

No data available :(

NGNE Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 243.2 million 6.1 million 9.5 million
Dec. 31, 2025 269.0 million - 6.8 million
Sept. 30, 2025 265.4 million - 11.3 million
June 30, 2025 274.5 million - 12.9 million

NGNE Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 22.3 million
Dec. 31, 2025 15.5 million
Sept. 30, 2025 21.2 million
June 30, 2025 21.1 million

NGNE Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 281000 25.2 million 8.2 million -
Dec. 31, 2025 114289 20.6 million 6.1 million -
Sept. 30, 2025 126109 17.2 million 6.6 million -
June 30, 2025 148000 19.4 million 6.7 million -

NGNE Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 854000
Dec. 31, 2025 - 787000
Sept. 30, 2025 - -
June 30, 2025 - 812000

NGNE

Price: $27.48

52 week price:
11.77
37.27

Earnings Per Share: -4.55 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 425.9 million

Links: